Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of arctiin in preparation of prostatic hyperplasia drugs

A technology of prostatic hyperplasia and arctiin, applied in the field of medicine, can solve the problems of continuous medication and troubles of BPH patients with adverse reactions, and achieve the effects of improving medication compliance, low toxic and side effects, and definite curative effect

Active Publication Date: 2021-11-02
SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above drugs are currently the most commonly used main drugs for the treatment of BPH, but they all have certain side effects, and when severe adverse reactions are caused, it will cause trouble for BPH patients to continue using the drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of arctiin in preparation of prostatic hyperplasia drugs
  • Application of arctiin in preparation of prostatic hyperplasia drugs
  • Application of arctiin in preparation of prostatic hyperplasia drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment one, arctiin injection

[0024] The arctiin injection formula and preparation method of the present embodiment are as follows:

[0025] The preparation method of arctiin is as follows:

[0026] S1: Take 10 kg of burdock seed coarse powder, add petroleum ether with a volume three times its weight, heat and reflux for 1 hour, discard the petroleum ether, and evaporate the dregs to dryness;

[0027] S2: Add 60% ethanol 3 times the volume of the weight of the burdock fruit, reflux once, 1 hour each time, combine the liquid medicine, filter, recover the ethanol under reduced pressure and concentrate, add an equal volume of water, stir evenly, filter, and take filtrate;

[0028] S3: Add the filtrate to the AB-8 macroporous adsorption column for adsorption, elute with 10% ethanol, collect 3 times the column volume of the eluate, recover the ethanol under reduced pressure and concentrate;

[0029] S4: Add dichloromethane-ethyl acetate-methanol (4:4:1) to crystalli...

Embodiment 2

[0033] Embodiment two, arctiin tablet

[0034] The arctiin tablet formula and preparation method of the present embodiment are as follows:

[0035] The preparation method of arctiin is as follows:

[0036] S1: Take 10 kg of burdock seed coarse powder, add petroleum ether with a volume three times its weight, heat and reflux for 1 hour, discard the petroleum ether, and evaporate the dregs to dryness;

[0037] S2: Add 60% ethanol 3 times the volume of the weight of the burdock fruit, reflux once, 1 hour each time, combine the liquid medicine, filter, recover the ethanol under reduced pressure and concentrate, add an equal volume of water, stir evenly, filter, and take filtrate;

[0038] S3: Add the filtrate to the AB-8 macroporous adsorption column for adsorption, elute with 10% ethanol, collect 3 times the column volume of the eluate, recover the ethanol under reduced pressure and concentrate;

[0039] S4: Add dichloromethane-ethyl acetate-methanol (4:4:1) to crystallize, se...

Embodiment 3

[0046] Embodiment three, animal modeling and administration

[0047] A total of 18 SD rats with a weight range of 250g±20g were selected, and the rats were randomly divided into 3 groups: normal control group, testosterone propionate group, testosterone propionate+arctiin group, 6 rats in each group. After one week of feeding to adapt to the environment, the testosterone propionate group and the testosterone propionate + arctiin group underwent surgical castration (removing the reproductive system, so as not to interfere with the amount of testosterone propionate added during the experiment), and were given testosterone propionate after one week of feeding Injection (4mg / kg / d) continuously for 28 days to create a model of benign prostatic hyperplasia in rats, testosterone propionate + arctiin group was given arctiin drug 0.1g / kg daily at the same time. After 28 days, they were killed, and the prostate tissue was taken to measure the wet weight and index of the prostate.

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of arctiin in preparation of a medicine for treating prostatic hyperplasia. Arctiin is a main active substance in fructus arctii, and it is found that arctiin can significantly reduce the wet weight and prostate index of prostate of a model animal and can be applied to treatment of prostatic hyperplasia. The arctiin is definite in curative effect and small in toxic and side effects, is expected to be developed into the prostatic hyperplasia medicine, and has a wide medical application prospect.

Description

technical field [0001] The application relates to the technical field of medicine, in particular to the application of arctiin in the preparation of prostatic hyperplasia medicine. Background technique [0002] benign prostate 増 Benign prostatic hyperplasia (BPH, referred to as benign prostatic hyperplasia) is a common disease that causes urinary system symptoms in middle-aged and elderly men, and is one of the common causes of voiding disorders in elderly men. The clinical manifestations of BPH include bladder irritation symptoms such as frequent urination, urgency, and nocturia, as well as obstructive symptoms such as thinning urinary stream, interruption of urine flow, and progressive dysuria, which may be accompanied by pain in the lower abdomen or perineum, sinking sensation, and low back pain. Other symptoms, severe BPH can cause secondary symptoms such as acute urinary retention or upper urinary tract lesions. The occurrence of BPH seriously affects the physical and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P13/08
CPCA61K31/7048A61P13/08
Inventor 谷猛王忠扬天页陈其达骏高大钧
Owner SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com